Antibe Therapeutics Inc(Pre-Merger) ATBPF

To do list ...

[MrMugsy]

Items still outstanding for 2022 ... 

1.  IBD update (calendar Q4)
2.  Presentation upate (assuming it follows the IBD update)
3.  Animal Studies to lead to acute/chronic dosing paths (Dec 2022 - Jan 2023)

-------------------------

Had an interesting discussion about IBD with insiders.  Will discuss that in more detail as we go.

What it seems we're looking at here is an attempt to reduce gut inflammation as much as possible.  cut off other inflammatory diseases at the source.

Then ... we can branch out from there. 

[Wriggles]

https://www.mdpi.com/2227-9059/10/1/85/htm   Thanks for posting Mugsy. I wonder if ATE is thinking oxidative stress (OS).   IBD is closely associated with OS. OS stems from excessive reactive oxygen species (ROS) and can lead to cell impairment. One way to tackle OS is by way of antioxidants which mitigate the effects of ROS.  This can be done more effectively with the use